Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
Fuji
McKinsey
Chinese Patent Office
AstraZeneca
Cipla
Daiichi Sankyo
US Department of Justice

Generated: February 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LETROZOLE

« Back to Dashboard

Clinical Trials for Letrozole

Trial ID Title Status Sponsor Phase Summary
NCT00001521 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia Active, not recruiting Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1 This study was developed to determine if a combination of four drugs (flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in children with congenital adrenal hyperplasia. The study will take 60 children, boys and girls and divide them into 2 groups based on the medications given. Group one will receive the new four- drug combination. Group two will receive the standard treatment for congenital adrenal hyperplasia (hydrocortisone and fludrocortisone). The boys in group one will take the medication until the age of 14 at which time they will stop taking the four drug combination and begin receiving the standard treatment for congenital adrenal hyperplasia. Girls in group one will take the four drug combination until the age of 13, at which time they will stop and begin receiving the standard treatment for congenital adrenal hyperplasia plus flutamide. Flutamide will be given to the girls until six months after their first menstrual period. All of the children will be followed until they reach their final adult height. The effectiveness of the treatment will be determined by measuring the patient's adult height, body mass index, and bone density.
NCT00003140 Letrozole After Tamoxifen in Treating Women With Breast Cancer Completed Cancer and Leukemia Group B Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 Letrozole After Tamoxifen in Treating Women With Breast Cancer Completed Eastern Cooperative Oncology Group Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 Letrozole After Tamoxifen in Treating Women With Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 Letrozole After Tamoxifen in Treating Women With Breast Cancer Completed International Breast Cancer Study Group Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 Letrozole After Tamoxifen in Treating Women With Breast Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Letrozole

Condition Name

Condition Name for Letrozole
Intervention Trials
Breast Cancer 153
Infertility 25
Breast Neoplasms 22
Metastatic Breast Cancer 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Letrozole
Intervention Trials
Breast Neoplasms 250
Infertility 33
Polycystic Ovary Syndrome 26
Syndrome 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Letrozole

Trials by Country

Trials by Country for Letrozole
Location Trials
Italy 167
Canada 104
Spain 93
United Kingdom 88
Japan 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Letrozole
Location Trials
California 63
Texas 62
Massachusetts 45
Florida 44
New York 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Letrozole

Clinical Trial Phase

Clinical Trial Phase for Letrozole
Clinical Trial Phase Trials
Phase 4 28
Phase 3 82
Phase 2/Phase 3 14
[disabled in preview] 204
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Letrozole
Clinical Trial Phase Trials
Completed 117
Recruiting 109
Active, not recruiting 55
[disabled in preview] 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Letrozole

Sponsor Name

Sponsor Name for Letrozole
Sponsor Trials
Novartis Pharmaceuticals 53
National Cancer Institute (NCI) 47
Novartis 27
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Letrozole
Sponsor Trials
Other 378
Industry 195
NIH 54
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Accenture
US Army
Johnson and Johnson
Medtronic
Teva
QuintilesIMS
Chinese Patent Office
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.